ReviewACS biomaterials science & engineering2021
Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.
Review in ACS biomaterials science & engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome.Current allergy and asthma reports · 2025Review
- Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases.Pharmaceutics · 2025Review
- Innovating Leishmaniasis Treatment: A Critical Chemist's Review of Inorganic Nanomaterials.ACS infectious diseases · 2024Review
- Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.Beilstein journal of nanotechnology · 2024Review
- Micro and nanotechnologies: The little formulations that could.Bioengineering & translational medicine · 2023Review
- Antiparasitic activity of the iron-containing milk protein lactoferrin and its potential derivatives against human intestinal and blood parasites.Frontiers in parasitology · 2023Review
- Liposomal drug delivery systems for the treatment of leishmaniasis.Parasitology research · 2022Review
- Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Visceral leishmaniasis (VL) is a deadly, vector-borne, neglected tropical disease endemic to arid parts of the world and is caused by a protozoan parasite of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.